Press Releases July 15, 2026 05:00 PM

ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of June 2026

ArrowMark Financial Corp. Announces Estimated Net Asset Value for June 2026

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
BANX

ArrowMark Financial Corp., a NASDAQ-listed closed-end fund focused on income generation through investments in financial institutions' regulatory capital securities, announced its estimated and unaudited Net Asset Value (NAV) as of June 30, 2026, at $21.00. The fund reminds investors of various risk factors and notes that this estimate is not a comprehensive financial statement.

ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of June 2026
BANX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Estimated NAV as of June 30, 2026, is $21.00, reflecting the fund's current valuation.
  • ArrowMark Financial's investment objective centers on providing shareholders with current income via investments in regulatory capital securities of financial institutions.
  • The fund highlights multiple risks including market, credit, leverage, and liquidity risks associated with closed-end fund investments in the banking sector.

DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of June 30, 2026, was $21.00.

This estimated NAV is not a comprehensive statement of our financial condition or results for the month end.

About ArrowMark Financial Corp.
ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the symbol “BANX.” Its investment objective is to provide shareholders with current income. BANX pursues its objective by investing primarily in regulatory capital securities of financial institutions. BANX is managed by ArrowMark Asset Management, LLC. To learn more, visit ir.arrowmarkfinancialcorp.com, or contact Destra at 877.855.3434 or by email at [email protected].

Disclaimer and Risk Factors:
There is no assurance that ArrowMark Financial will achieve its investment objective. ArrowMark Financial is subject to numerous risks, including investment and market risks, management risk, income and interest rate risks, banking industry risks, preferred stock risk, convertible securities risk, debt securities risk, liquidity risk, valuation risk, leverage risk, non-diversification risk, credit and counterparty risks, market at a discount from net asset value risk and market disruption risk. Shares of closed-end investment companies may trade above (a premium) or below (a discount) their net asset value. Shares of ArrowMark Financial may not be appropriate for all investors. Investors should review and consider carefully ArrowMark Financial's investment objective, risks, charges and expenses. Past performance does not guarantee future results.

The Annual Report, Semi-Annual Report and other regulatory filings of the Company with the SEC are accessible on the SEC's website at www.sec.gov and on the BANX’s website at ir.arrowmarkfinancialcorp.com.

Contact:
[email protected]


Risks

  • Investment and market risks inherent in the financial sector affecting the value and income potential of regulatory capital securities.
  • Credit and counterparty risks related to the quality of financial institution securities held.
  • Market fluctuation risks including trading at prices above or below NAV, liquidity risk, and potential market disruptions impacting valuation and investor returns.

More from Press Releases

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 Aug 29, 2026 Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 Aug 29, 2026 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity Aug 28, 2026 Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update Aug 28, 2026 AiRWA receives expected notification of deficiency from Nasdaq related to delayed filing of annual report on Form 10-K Aug 28, 2026